Find relevant news articles from other European projects, below:
Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:
Chemo-free therapy for adult Ph+ ALL
A targeted and immunotherapeutic strategy including dasatinib and the bispecific mAb blinatumomab is able to successfully treat adult patients with Philadelphia-positive acute lymphoblastic leukemia (ALL), inducing 98% of hematological CR and 60% of molecular responses. These results, published on NEJM, were obtained without adding of chemotherapy, an innovative approach associated with high survival rates and few toxic effects.